Goldman Sachs Initiates Pharmerica With Neutral

Analysts at Goldman Sachs initiated coverage on shares of Pharmerica

with a Neutral rating. The target price for Pharmerica is set to $29. Pharmerica shares have surged 102.34% over the past 52 weeks, while the S&P 500 index has gained 18.15% in the same period. Pharmerica's shares jumped 5.19% to close at $25.96 yesterday.